MX2017000184A - Agentes de interaccion enzimatica. - Google Patents

Agentes de interaccion enzimatica.

Info

Publication number
MX2017000184A
MX2017000184A MX2017000184A MX2017000184A MX2017000184A MX 2017000184 A MX2017000184 A MX 2017000184A MX 2017000184 A MX2017000184 A MX 2017000184A MX 2017000184 A MX2017000184 A MX 2017000184A MX 2017000184 A MX2017000184 A MX 2017000184A
Authority
MX
Mexico
Prior art keywords
compounds
agents
enzyme interacting
interacting agents
enzyme
Prior art date
Application number
MX2017000184A
Other languages
English (en)
Inventor
Luke Flynn Bernard
Aurelio Luigi
Vittoria SCULLINO Carmen
Hui Wang Bing
Maxwell Pitson Stuart
Rose Pitman Melissa
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902459A external-priority patent/AU2014902459A0/en
Application filed by Univ Monash filed Critical Univ Monash
Publication of MX2017000184A publication Critical patent/MX2017000184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente divulgación se refiere en general, pero no exclusivamente, a compuestos y a su uso como agentes de interacción enzimática, en particular, agentes que interactúan con una o más enzimas en la ruta de biosíntesis de esfingolípidos. La divulgación se refiere además al uso de tales compuestos como herramientas de investigación, uso en terapia, a composiciones y agentes que comprenden dichos compuestos, y a métodos de tratamiento que usan dichos compuestos.
MX2017000184A 2014-06-26 2015-06-26 Agentes de interaccion enzimatica. MX2017000184A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014902459A AU2014902459A0 (en) 2014-06-26 Targeting agents
PCT/AU2015/050358 WO2015196258A1 (en) 2014-06-26 2015-06-26 Enzyme interacting agents

Publications (1)

Publication Number Publication Date
MX2017000184A true MX2017000184A (es) 2017-09-15

Family

ID=54936357

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000184A MX2017000184A (es) 2014-06-26 2015-06-26 Agentes de interaccion enzimatica.

Country Status (8)

Country Link
US (1) US9828351B2 (es)
EP (1) EP3160949A4 (es)
JP (1) JP6615876B2 (es)
CN (1) CN107614491A (es)
AU (1) AU2015281799B2 (es)
CA (1) CA2990028A1 (es)
MX (1) MX2017000184A (es)
WO (1) WO2015196258A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135207B2 (en) 2016-12-13 2021-10-05 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
BR112022001270A2 (pt) 2019-07-24 2022-06-14 Cincera Therapeutics Pty Ltd Compostos inibidores
CN115551883A (zh) * 2020-03-20 2022-12-30 蒙纳什大学 用于治疗狼疮的组合物和方法
CN116210706B (zh) * 2023-02-03 2024-05-10 河北工业大学 生物碱polyaurine B衍生物在抗植物病毒和病菌中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2923661A (en) 1957-03-22 1960-02-02 Irwin Neisler And Co N-[2-(1-phenyl-propyl)]-2, 2, 2-trichloroethylidenimine
FR2073284B1 (es) 1969-12-23 1973-07-13 Ferlux
ATE49198T1 (de) * 1984-05-12 1990-01-15 Fisons Plc Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung.
DE3773746D1 (en) * 1986-05-07 1991-11-21 Fisons Plc Pyrazole.
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
FI982268A7 (fi) 1998-10-20 2000-04-21 Jarkko Rautio Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen uudet prodrugit, niiden valmistus ja käyttö
DE19939910A1 (de) 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
EP1432693A2 (en) 2001-10-01 2004-06-30 Taisho Pharmaceutical Co. Ltd. Mch receptor antagonists
EP1467981A1 (en) * 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
WO2003105840A2 (en) * 2002-06-17 2003-12-24 The Pennsylvania State Research Foundation Sphingosine kinase inhibitors
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US20070032531A1 (en) * 2005-08-04 2007-02-08 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
JP5222561B2 (ja) * 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
EP2109364A4 (en) * 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
MX2010003612A (es) * 2007-10-04 2010-04-30 Merck Serono Sa Derivados de oxadiazol.
US20090291967A1 (en) * 2008-03-05 2009-11-26 Adherex Technologies, Inc. Small molecule modulators of cell adhesion
CA2721060A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
KR101582910B1 (ko) * 2008-05-14 2016-01-08 더 스크립스 리서치 인스티튜트 스핑고신 포스페이트 수용체의 신규한 모듈레이터
EP3782991A1 (en) * 2008-05-14 2021-02-24 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
TW201120016A (en) * 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
KR101889131B1 (ko) * 2011-12-23 2018-09-20 메이지 세이카 파루마 가부시키가이샤 신규 s1p 수용체 조정제
US9120784B2 (en) * 2012-11-05 2015-09-01 Allergan, Inc. 1,3,4-oxadiazoles-2-thio azetidine derivatives as sphingosine-1 phosphate receptors modulators
KR101559883B1 (ko) 2013-10-30 2015-10-13 동국대학교 산학협력단 2-아미노치환 옥사디아졸 유도체, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
JP2017526733A (ja) 2017-09-14
US9828351B2 (en) 2017-11-28
AU2015281799A1 (en) 2017-01-12
AU2015281799B2 (en) 2019-11-28
EP3160949A4 (en) 2018-01-17
EP3160949A1 (en) 2017-05-03
CA2990028A1 (en) 2015-12-30
JP6615876B2 (ja) 2019-12-04
CN107614491A (zh) 2018-01-19
WO2015196258A1 (en) 2015-12-30
US20170190698A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
AU2019264537A1 (en) Beta-lactamase inhibitors
PH12019502279A1 (en) Cleaning compositions and uses thereof
PH12017501481A1 (en) Bicyclic heterocycles as fgfr inhibitors
MX2016000719A (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
MX389228B (es) Composiciones para tratar el cabello.
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
MX361862B (es) Composiciones y métodos que comprenden variante de enzima lipolítica.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
MX362812B (es) Metodos y composiciones para el control de malezas.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
SG10201804952QA (en) Glucosylceramide synthase inhibitors
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
MY181766A (en) Salt forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
TW201614069A (en) Inhibitors of MYH7B and uses thereof
SG10201900041VA (en) Meningococcus vaccines
NZ701463A (en) Anti-phytopathogenic composition
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
MX2017000184A (es) Agentes de interaccion enzimatica.
WO2014165713A3 (en) Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
BR112017024855A2 (pt) métodos de produção de aldc
MY198644A (en) Enzyme composition